CAS 729607-74-3|BMS-707035

Introduction：Basic information about CAS 729607-74-3|BMS-707035, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. BMS-707035 BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	BMS-707035
CAS Number	729607-74-3	Molecular Weight	410.420
Density	1.5±0.1 g/cm3	Boiling Point	/
Molecular Formula	C₁₇H₁₉FN₄O₅S	Melting Point	/
MSDS	/	Flash Point	/

Names

Name	2-(1,1-dioxothiazinan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide
Synonym	More Synonyms

BMS-707035 BiologicalActivity

Description	BMS-707035 is an HIV-1 integrase (IN) inhibitor with an IC50 value of 15 nM. IC50 Value: 15 nMTarget: HIV IntegraseBMS-707035 was scheduled to be evaluated in a Phase II study to assess the antiretroviral activity, safety, pharmacodynamics, and pharmacokinetics in 50 HIV-infected subjects using a 10-day randomized, double-blind, placebo-controlled, ascending multiple-dose study design.
Related Catalog	Signaling Pathways >>Metabolic Enzyme/Protease >>HIV IntegraseSignaling Pathways >>Anti-infection >>HIVResearch Areas >>Infection
References	[1]. Cotelle P.,3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.,Expert Opin Ther Pat. 2011 Nov;21(11):1799-804. [2]. Al-Mawsawi LQ, Al-Safi RI, Neamati N.,Anti-infectives: clinical progress of HIV-1 integrase inhibitors.,Expert Opin Emerg Drugs. 2008 Jun;13(2):213-25. [3]. Dayam R, Al-Mawsawi LQ, Neamati N.,HIV-1 integrase inhibitors: an emerging clinical reality.,Drugs R D. 2007;8(3):155-68. [4]. Dicker IB, et al. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem. 2007 Oct 26;282(43):31186-96.

Description

BMS-707035 is an HIV-1 integrase (IN) inhibitor with an IC50 value of 15 nM. IC50 Value: 15 nMTarget: HIV IntegraseBMS-707035 was scheduled to be evaluated in a Phase II study to assess the antiretroviral activity, safety, pharmacodynamics, and pharmacokinetics in 50 HIV-infected subjects using a 10-day randomized, double-blind, placebo-controlled, ascending multiple-dose study design.

Related Catalog

Signaling Pathways >>Metabolic Enzyme/Protease >>HIV IntegraseSignaling Pathways >>Anti-infection >>HIVResearch Areas >>Infection

References

[1]. Cotelle P.,3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.,Expert Opin Ther Pat. 2011 Nov;21(11):1799-804.

[2]. Al-Mawsawi LQ, Al-Safi RI, Neamati N.,Anti-infectives: clinical progress of HIV-1 integrase inhibitors.,Expert Opin Emerg Drugs. 2008 Jun;13(2):213-25.

[3]. Dayam R, Al-Mawsawi LQ, Neamati N.,HIV-1 integrase inhibitors: an emerging clinical reality.,Drugs R D. 2007;8(3):155-68.

[4]. Dicker IB, et al. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem. 2007 Oct 26;282(43):31186-96.

Chemical & Physical Properties

Density	1.5±0.1 g/cm3
Molecular Formula	C₁₇H₁₉FN₄O₅S
Molecular Weight	410.420
Exact Mass	410.106018
PSA	133.47000
LogP	-2.04
Index of Refraction	1.670
Storage condition	-20℃

Synonyms

4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)-

HIV Integrase Inhibitor

S1366_Selleck

UNII-7PR4P7YOKT

2-(1,1-Dioxido-1,2-thiazinan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-4-pyrimidinecarboxamide

BMS-707035

Recommended......